WealthPLAN Partners LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 1,927.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 5,088 shares of the medical instruments supplier’s stock after acquiring an additional 4,837 shares during the period. WealthPLAN Partners LLC’s holdings in Becton, Dickinson and were worth $993,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Janney Montgomery Scott LLC lifted its stake in Becton, Dickinson and by 35.3% during the second quarter. Janney Montgomery Scott LLC now owns 43,293 shares of the medical instruments supplier’s stock worth $8,447,000 after purchasing an additional 11,300 shares in the last quarter. Bessemer Group Inc. lifted its stake in Becton, Dickinson and by 1.4% during the second quarter. Bessemer Group Inc. now owns 978,050 shares of the medical instruments supplier’s stock worth $190,827,000 after purchasing an additional 13,263 shares in the last quarter. Pictet Asset Management Ltd. lifted its stake in Becton, Dickinson and by 9.3% during the second quarter. Pictet Asset Management Ltd. now owns 246,404 shares of the medical instruments supplier’s stock worth $46,627,000 after purchasing an additional 21,022 shares in the last quarter. Union Bankshares Corp lifted its stake in Becton, Dickinson and by 1.7% during the second quarter. Union Bankshares Corp now owns 22,335 shares of the medical instruments supplier’s stock worth $4,357,000 after purchasing an additional 381 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in Becton, Dickinson and by 5.8% during the second quarter. State of Alaska Department of Revenue now owns 32,999 shares of the medical instruments supplier’s stock worth $6,438,000 after purchasing an additional 1,819 shares in the last quarter. Institutional investors own 87.12% of the company’s stock.

A number of research analysts have commented on the company. BidaskClub upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company restated an “outperform” rating and set a $230.00 price target (up from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Barclays PLC restated an “equal weight” rating and set a $210.00 price target (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 price target on the stock in a research note on Monday, July 17th. Finally, Wells Fargo & Company assumed coverage on Becton, Dickinson and in a research note on Friday, September 22nd. They set an “outperform” rating and a $225.00 price target on the stock. One analyst has rated the stock with a sell rating, four have given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $200.93.

In other Becton, Dickinson and news, EVP Ribo Alberto Mas sold 7,463 shares of the business’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $201.41, for a total value of $1,503,122.83. Following the transaction, the executive vice president now owns 29,323 shares in the company, valued at approximately $5,905,945.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary M. Cohen sold 15,512 shares of the business’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total transaction of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders sold a total of 75,904 shares of company stock worth $15,242,688 in the last quarter. 1.40% of the stock is currently owned by company insiders.

WARNING: This piece was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://theolympiareport.com/2017/10/18/wealthplan-partners-llc-has-993000-position-in-becton-dickinson-and-company-bdx.html.

Shares of Becton, Dickinson and Company (BDX) opened at 203.07 on Wednesday. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The firm has a market capitalization of $46.21 billion, a PE ratio of 58.81 and a beta of 1.05. The stock has a 50 day moving average price of $197.13 and a 200 day moving average price of $193.13.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The business had revenue of $3.04 billion for the quarter, compared to analyst estimates of $3.06 billion. During the same quarter in the previous year, the business posted $2.35 EPS. The business’s quarterly revenue was down 5.1% on a year-over-year basis. Equities analysts forecast that Becton, Dickinson and Company will post $9.46 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 29th. Shareholders of record on Friday, September 8th were issued a $0.73 dividend. The ex-dividend date was Thursday, September 7th. This represents a $2.92 dividend on an annualized basis and a yield of 1.44%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.

Becton, Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.